We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
NeuroMetrix, Inc. (NURO) on Tuesday said the company and GlaxoSmithKline PLC (GSK) agreed to co-fund future development of Quell technology beginning in 2019, "subject to agreement on an annual program of product initiatives."
NeuroMetrix said the 2019 development program will commence in January.
The two companies also modified terms of their collaboration which will see the up to $13.8 million remaining to be paid by GlaxoSmithKline upon the achievement of certain milestones reallocated. NeuroMetrix said it received a $2 million milestone payment from GlaxoSmithKline in connection with such modifications.
In January, the two companies announced a collaboration which saw GSK acquire exclusive ownership of Quell technology for markets outside the U.S., while NeuroMetrix retained exclusive ownership in the U.S. market. Quell is a wearable device designed to ease chronic pain.
Trading in NeuroMetrix shares had been briefly halted Tuesday afternoon prior to the announcement. At 1:42 p.m. EST, shares were trading up 15.87% at 98 cents per share.
American depository receipts of GlaxoSmithKline were trading down 0.78% at $37.38.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 11, 2018 14:03 ET (19:03 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
